KUALA LUMPUR, Sept 30 — Duopharma Biotech Bhd has appointed Wan Amir-Jeffery Wan Abdul Majid as its Group Chief Executive Officer, effective October 1, 2025. Prior to this appointment, Wan Amir-Jeffery was Duopharma Biotech’s Chief Executive Officer – Group Operations.
Kartini Abdul Manaf, chairman of Duopharma Biotech said, “I congratulate Wan Amir-Jeffery on his appointment as the Group Chief Executive Officer of Duopharma Biotech.
“In his tenure of service since joining us, he has contributed immensely to the company strategically and operationally. I am confident that Duopharma Biotech will continue its healthy growth trajectory, strengthening its position as a leading pharmaceutical company in Malaysia.”
Wan Amir-Jeffery joined Duopharma Biotech in September 2016 as Chief Strategy Officer. In 2018, he was promoted to Chief Operating Officer, and two years later, in 2020, he assumed the role of Chief Commercial Officer.
In 2022, he was elevated to Chief Executive Officer – Commercial. After two years, in 2024, he was appointed as Chief Executive Officer – Group Operations.
He holds a Bachelor of Business Administration (International Trade) degree from the University of Central Arkansas, and is an alumnus of the Senior Management Development Program at Harvard Business School.
Wan Amir-Jeffery is also a Vice-President of the Malaysian Organisation of Pharmaceutical Industries (MOPI) for the 2025–2027 term.
